100P SPOTLIGHT real-world study: Patient characteristics and treatment patterns in patients with unresectable stage III NSCLC receiving durvalumab after chemoradiotherapy (CRT)

Mooradian, Meghan J.; Allen, A.; Cai, Ling; Xiao, Yu; Chander, Pratibha

doi:10.1016/j.annonc.2021.10.118

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…If evidence regarding stage IV increases, the management of isolated distant relapse during durvalumab consolidation in stage III NSCLC is still an unmet need. According to different real-world series, 20-30% of patients experience distant relapse during durvalumab treatment, with the brain being one of the most common sites of relapse [17][18][19]. To the best of our knowledge, there is no evidence about the best therapeutic management in this setting, or about a possible durvalumab continuation and integration with loco-regional treatments.…”

Section: Discussionmentioning

confidence: 99%

Oligorecurrent Non-Small-Cell Lung Cancer Treated by Chemo-Radiation Followed by Immunotherapy and Intracranial Radiosurgery: A Case Report and Mini Review of Literature

Bruni

Bertolini

D’Angelo

et al. 2023

IJMS

View full text Add to dashboard Cite

Locally advanced non-small-cell lung cancer still represents a “grey zone” in terms of the best treatment choice and optimal clinical outcomes. Indeed, most patients may be suitable to receive different treatments with similar outcomes such as chemo-radiotherapy (CHT-RT) followed by immunotherapy (IO) or surgery followed by adjuvant local/systemic therapies. We report a clinical case of a patient submitted to primary thoracic surgery who developed a mediastinal nodal recurrence successfully treated by CHT-RT-IO. Subsequently, a single brain lesion was found to have been successfully treated by single fraction stereotactic ablative radiotherapy. The patient is still on follow-up and she is free from disease having a good quality of life. In this report, we also perform a mini review about the role of CHT-RT followed by IO in treating loco-regional relapse after surgery. The role of SABR after IO is also evaluated, finding that it is safe and well tolerated. More robust and larger clinical data are needed in this particular setting to better define the role of the combination of systemic and local treatments in the management of intrathoracic and intracranial relapse for patients already submitted to CHT-RT followed by immunotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%